drug · antibody
patient view →pozelimab
Phase 3updated 2mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for protein-losing enteropathy and 2 investigational indications.
targets
Complement C5
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that